CJC-1295 w/ DAC (5 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

CJC-1295 with DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). The Drug Affinity Complex (DAC) modification lets the molecule bind reversibly to circulating albumin, which stretches its functional half-life out to roughly 6–8 days. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound is handled and measured, not a recommendation for use in humans or animals.

For a 5 mg vial, adding 2.0 mL of bacteriostatic water produces a concentration of 2.5 mg/mL (2,500 mcg/mL). At that fill, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 250 mcg of material, which keeps the math tidy across the titration steps below.

Standard (Gradual) Titration Schedule

The gradual schedule steps the per-injection amount up every couple of weeks, using a twice-weekly cadence with injections spaced roughly 3–4 days apart. Because the DAC version is long-acting, the protocol favours a slow build to a steady plateau rather than frequent dosing.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 2.0 mL of bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, to avoid foaming.
3. Gently swirl or roll the vial until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. Confirm the solution is clear and colourless. Label the vial with the concentration (2.5 mg/mL) and the reconstitution date.
5. Refrigerate upright at 2–8 °C, protected from light, and draw each subsequent volume with a fresh sterile syringe.

Maintenance (Plateau) Schedule

Once the gradual build reaches its ceiling, the protocol holds a flat maintenance level for the remainder of the cycle. Because the DAC anchor keeps blood levels elevated for several days, the plateau is held at the same twice-weekly cadence rather than escalating further.

Supplies Needed

• CJC-1295 w/ DAC vials (5 mg): ~3 vials cover a standard 8-week run (about 10.2 mg of material used); budget more for a 12–16 week cycle.
• Insulin syringes (U-100, 1 mL): ~16 for an 8-week schedule (one fresh syringe per injection); ~24 for a 12-week cycle.
• Bacteriostatic water (10 mL): one bottle is ample — roughly 6 mL is consumed reconstituting three vials.
• Alcohol swabs: a single 100-count box (about 32 swabs used over 8 weeks) comfortably covers the run.

Protocol Overview

• Research goal: model sustained growth-hormone and IGF-1 elevation via long-acting GHRH-receptor stimulation.
• Schedule: twice-weekly subcutaneous administration, injections 3–4 days apart.
• Dose band: 300–1000 mcg per injection (600–2000 mcg weekly).
• Fill: 5 mg lyophilized, reconstituted to 2.5 mg/mL with 2 mL diluent.
• Cycle: 8–12 weeks, optional extension to 16 weeks.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 300 mcg step and hold each level for about two weeks before stepping up.
• Keep injections on a fixed twice-weekly cadence with consistent 3–4 day spacing for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Because the DAC half-life is long, additional same-week dosing offers little benefit and is not part of the model.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F), in dry, dark conditions, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 2–4 weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and protect the vial from light throughout.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Roll or swirl to mix — never shake — to preserve peptide integrity.
• Keep the vial upright and refrigerated between draws; protect from light.
• Document each draw — date, volume, remaining material — for reproducibility.

How CJC-1295 w/ DAC Works

CJC-1295 is a modified 29-amino-acid GHRH fragment that binds pituitary GHRH receptors and stimulates the synthesis and release of growth hormone. The DAC (Drug Affinity Complex) addition is a small chemical group that forms a reversible bond with serum albumin, shielding the peptide from rapid enzymatic breakdown and renal clearance. That albumin tethering is what extends the functional half-life to roughly 6–8 days, producing a sustained rather than pulsatile rise in circulating GH and downstream IGF-1 in the published literature. The effect is dose-dependent across the studied range.

Reported Benefits & Side Effects

Benefits reported in studies

• Sustained, dose-dependent elevation of growth hormone and IGF-1 across the dosing window.
• Signals associated with increased lean body mass and reduced fat mass in body-composition models.
• Enhanced protein-synthesis and recovery signalling through anabolic pathways.
• Generally well tolerated in the clinical studies that evaluated it.

Side effects reported

• Occasional mild injection-site reactions such as redness or swelling.
• Transient flushing, headache or mild water retention, most often during early titration.
• Effects generally described as mild and self-limiting.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition to support IGF-1-driven anabolic signalling.
• Combined resistance and aerobic activity in body-composition study designs.
• Adequate sleep, since the bulk of natural GH release coincides with deep sleep cycles.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol and let both dry before drawing.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then withdraw — do not rub or massage the site afterward.
• Rotate sites systematically across the abdomen, thighs and upper arms to avoid lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols